Jiangsu Kanion Pharmaceutical Co. Ltd. Class A

Jiangsu Kanion Pharmaceutical Co. Ltd. Class A

SSSE:600557
12.14
CNY
0.00
(0.00%)
0.56EPS
22.04P/E
6.96BMarket Cap
Apr 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.75
4.28
4.59
4.9
5.52
6.47
7.74
5.07
6.37
7.51
8.49
6.76
5.85
5.97
Basic EPS, GAAP
0.5
0.53
0.59
0.61
0.63
0.7
0.86
0.44
0.56
0.75
0.81
0.68
0.54
0.56
Free Cash Flow per Basic Share
0.08
- -
0.23
-0.04
0.21
0.57
0.74
0.85
1.29
1.35
1.15
0.39
0.16
- -
Dividend per Share
0.14
0.17
0.14
0.1
0.15
0.14
0.14
0.11
0.02
- -
0.22
0.37
0.16
- -
Book Value per Share
3.14
4.05
4.56
5.1
5.65
6.31
6.64
7.03
7.26
8.13
8.45
7.76
8.51
8.8
Tangible Book Value per Share
2.67
3.58
3.95
4.38
4.88
5.44
5.79
6.12
6.43
7.35
7.71
7.04
7.69
7.93
Basic Weighted Avg Shares
594
599
614
613
593
592
590
598
572
579
573
576
563
565
Sales/Revenue/Turnover
2,230
2,563
2,820
3,000
3,275
3,825
4,566
3,032
3,649
4,351
4,864
3,898
3,293
3,373
Operating Margin (%)
16.34
16.86
15.84
14.36
14.99
13.89
13.42
12.19
9.65
10.16
9.2
9.9
11.39
10.97
Depreciation Expense
63
89
107
139
150
163
166
160
187
190
195
200
191
- -
Net Income, GAAP
297
320
362
374
374
414
507
263
321
434
464
392
304
316
Effective Tax Rate (%)
13.24
13.26
12.78
12.42
13.83
12.2
10.23
6.93
1.19
0.85
0.88
1
13.82
12.55
Profit Margin (%)
13.32
12.47
12.85
12.46
11.41
10.83
11.1
8.67
8.79
9.99
9.54
10.05
9.23
9.36
Working Capital
448
830
881
904
1,094
1,133
977
1,190
1,421
1,949
2,033
1,551
1,592
1,461
LT Debt
167
125
45
- -
2
2
2
- -
- -
- -
- -
- -
1
1
Total Equity
1,935
2,556
2,871
3,206
3,594
4,014
4,087
4,327
4,473
4,934
5,019
4,705
5,012
5,179
Return on Invested Capital (%)
9.84
9.96
10.14
9.78
9.65
9.34
10.88
6.78
7.25
9.25
9.06
7.77
6.53
6.42
Return on Capital (%)
12.81
12.07
11.79
11.98
10.66
9.98
11.26
5.71
6.88
8.9
9.73
8.74
6.44
6.54
Return on Common Equity (%)
17.02
14.6
13.65
12.55
11.28
11.23
12.96
6.49
7.57
9.59
9.58
8.29
6.51
6.55

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
566
566
566
Market Capitalization
7,717
6,664
6,964

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,206
3,193
3,088
Cash, Cash Equivalents & STI
2,036
1,957
2,039
Accounts Receivable, Net
488
517
418
Inventories
458
406
375
Total Current Liabilities
1,657
1,665
1,628
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.88%
3.14%
6.53%
Free Cash Flow
-55.26%
-18.3%
-60.67%
Net Income, GAAP
1.45%
5.25%
-22.44%
Sales/Revenue/Turnover
3.41%
3.2%
-15.52%
Total Cash Common Dividend
490.77%
982.69%
-56.97%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,358
901
850
788
3,898
2025
878
764
- -
950
3,293
2026
831
830
761
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.2
0.16
0.06
0.68
2025
0.15
0.1
- -
0.18
0.54
2026
0.14
0.12
0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.37
- -
- -
0.37
2025
- -
- -
- -
- -
0.16
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yong Chun Yang
Full Time Employees
5,379
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Economic and development zone Lianyungang JS China 222000
IPO Date
Sep 18, 2002
Website
kanion.com
Business
I did not find specific data regarding recent changes, partnerships, funding, acquisitions, or product launches for Jiangsu Kanion Pharmaceutical Co., Ltd. (Ticker: 600557.SS) in the search results explicitly. To provide a comprehensive and updated description, I will now search for detailed company profile information and latest news related directly to Jiangsu Kanion Pharmaceutical Co., Ltd. and its ticker 600557.SS.